Kudrna's Stock Market Talk

Due to time constraints this week (yet again), this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix the deficit (without being able to print money), among other areas.  I look forward to resuming the normal article schedule in the coming months.  Remember, I’m a trader first and an author second which keeps this site free. Make sure you spend some time in the live-chat with our other seasoned traders, this is probably our best feature on the site.   (more…)

Due to time constraints this week (yet again), this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix the deficit (without being able to print money), among other areas.  I look forward to resuming the normal article schedule in the coming months.  Remember, I’m a trader first and an author second which keeps this site free. Make sure you spend some time in the live-chat with our other seasoned traders, this is probably our best feature on the site.   (more…)

Due to time constraints this week (yet again), this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix the deficit (without being able to print money), among other areas.  I look forward to resuming the normal article schedule in the coming months.  Remember, I’m a trader first and an author second which keeps this site free. Make sure you spend some time in the live-chat with our other seasoned traders, this is probably our best feature on the site.   (more…)

Due to time constraints this week, this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix the deficit (without being able to print money), among other areas.  Hopefully I can resume the normal article schedule late this summer.  Remember, I’m a trader first and an author second which keeps this site free. Make sure you spend some time in the live-chat with our other seasoned traders, this is probably our best feature on the site.   (more…)

Due to time constraints this week, this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix the deficit (without being able to print money), among other areas.  Hopefully I can resume the normal article schedule late this summer.  Remember, I’m a trader first and an author second which keeps this site free. Make sure you spend some time in the live-chat with our other seasoned traders, this is probably our best feature on the site.   (more…)

On June 21, 2012, Depomed (DEPO) announced the acquisition of the product Zipsor (diclofenac potassium) Liquid Filled Capsules from privately-held Xanodyne Pharmaceuticals, Inc. Zipsor is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults. The product uses the proprietary ProSorb delivery technology (developed by AAIPharma Services Corp) to deliver a finely dispersed, rapidly absorbed formulation of diclofenac.

Zipsor is the lowest prescription-strength diclofenac available. The ProSorb technology allows for rapid delivery and dispersion of the medicine. The low-dose offers minimal systemic drug exposure. Depomed believes these advantages will help them drive Zipsor sales in the coming years. (more…)

Due to time constraints this week, this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix the deficit (without being able to print money), among other areas.  Hopefully I can resume the normal article schedule this summer.  Remember, I’m a trader first and an author second which keeps this site free. Make sure you spend some time in the live-chat with our other seasoned traders as well as keep up to date with our other authors on the site.   (more…)

Due to time constraints this week, this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix the deficit (without being able to print money), among other areas.  Hopefully I can resume the normal article schedule this summer.  Remember, I’m a trader first and an author second which keeps this site free. Make sure you spend some time in the live-chat with our other seasoned traders as well as keep up to date with our other authors on the site.   (more…)

Due to time constraints this week, this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix the deficit (without being able to print money), among other areas.  Hopefully I can resume the normal article schedule this summer.  Remember, I’m a trader first and an author second which keeps this site free. Make sure you spend some time in the live-chat with our other seasoned traders as well as keep up to date with our other authors on the site.  (more…)

On June 5, 2012, Abbott Labs (NYSE:ABT) and Neurocrine Biosciences (NASDAQ:NBIX) announced that they had initiated a pivotal phase 3 clinical study designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis. Abbott designed the protocol of the trial after over a year of back-and-forth discussion with the U.S. FDA, but chose not to pursue a formal SPA to avoid further delay in the start of the program. (more…)